Skip to main content
SpringerLink
Log in

A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation

  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The objective of this study was to develop an efficient tumor vasculature targeted liposome delivery system for combretastatin A4, a novel antivascular agent. Liposomes composed of hydrogenated soybean phosphatidylcholine (HSPC), cholesterol, distearoyl phosphoethanolamine-polyethylene-glycol-2000 conjugate (DSPE-PEG), and DSPE-PEG-maleimide were prepared by the lipid film hydration and extrusion process. Cyclic RGD (Arg-Gly-Asp) peptides with affinity for αvβ3-integrins expressed on tumor vascular endothelial cells were coupled to the distal end of PEG on the liposomes sterically stabilized with PEG (long circulating liposomes, LCL). The liposome delivery system was characterized in terms of size, lamellarity, ligand density, drug loading, and leakage properties. Targeting nature of the delivery system was evaluated in vitro using cultured human umbilical vein endothelial cells (HUVEC). Electron microscopic observations of the formulations revealed presence of small unilamellar liposomes of ∼120 nm in diameter. High performance liquid chromatography determination of ligand coupling to the liposome surface indicated that more than 99% of the RGD peptides were reacted with maleimide groups on the liposome surface. Up to 3 mg/mL of stable liposomal combretastatin A4 loading was achieved with ∼80% of this being entrapped within the liposomes. In the in vitro cell culture studies, targeted liposomes showed significantly higher binding to their target cells than non-targeted liposomes, presumably through specific interaction of the RGD with its receptors on the cell surface. It was concluded that the targeting properties of the prepared delivery system would potentially improve the therapeutic benefits of combretastatin A4 compared with nontargeted liposomes or solution dosage forms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lasic DD, Papahadjopoulos D. Medical Applications of Liposomes. Amsterdam, The Netherlands: Elsevier; 1998.

    Google Scholar 

  2. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992; 52: 3255–3261.

    CAS  Google Scholar 

  3. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 1997; 118: 153–160.

    Article  CAS  Google Scholar 

  4. Stephenson SM, Low PS, Lee RJ. Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol. 2004; 387: 33–50.

    Article  Google Scholar 

  5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997; 57: 1829–1834.

    CAS  Google Scholar 

  6. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs. 2004; 13: 1171–1182.

    Article  Google Scholar 

  7. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002; 8: 918–921.

    Article  CAS  Google Scholar 

  8. Kumar CC, Armstrong L, Yin Z, et al. Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol. 2000; 476: 169–180.

    CAS  Google Scholar 

  9. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alpha v beta 3 antagonists. J Am Chem Soc. 1996; 118: 7461–7472.

    Article  CAS  Google Scholar 

  10. Pattillo CB, Sari-Sarraf F, Nallamothu R, Moore BM, Wood GC, Kiani MF. Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm Res. 2005; 22: 1117–1120.

    Article  CAS  Google Scholar 

  11. Pettit GR, Singh SB, Boyd MR, et al. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J Med Chem. 1995; 38: 1666–1672.

    Article  CAS  Google Scholar 

  12. Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta. 1985; 812: 55–65.

    Article  CAS  Google Scholar 

  13. New RRC, Black CDV, Parker RJ, Puri A, Scherphof GL. Liposomes in biological systems. In: New RRC, ed. Liposomes: A Practical Approach. Oxford, UK: IRL Press Ltd; 1993: 221–252.

    Google Scholar 

  14. Prabhakarpandian B, Goetz DJ, Swerlick RA, Chen X, Kiani MF. Expression and functional significance of E-selectin on cultured endothelial cells in response to ionizing radiation. Microcirculation. 2001; 8: 355–364.

    Article  CAS  Google Scholar 

  15. Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target. 1996; 3: 391–398.

    Article  CAS  Google Scholar 

  16. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J. 1980; 186: 591–598.

    CAS  Google Scholar 

  17. Semple SC, Chonn A, Cullis PR. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry. 1996; 35: 2521–2525.

    Article  CAS  Google Scholar 

  18. Torchilin VP, Omelyanenko VG, Papisov MI, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta. 1994; 1195: 11–20.

    Article  CAS  Google Scholar 

  19. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta. 1995; 1239: 133–144.

    Article  Google Scholar 

  20. Martin FJ, Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles: an improved method for liposome targeting. J Biol Chem. 1982; 257: 286–288.

    CAS  Google Scholar 

  21. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta. 1995; 1237: 99–108.

    Article  Google Scholar 

  22. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001; 1: 923–947.

    Article  CAS  Google Scholar 

  23. Rouser G, Fkeischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970; 5: 494–496.

    Article  CAS  Google Scholar 

  24. Kawahara K, Sekiguchi A, Kiyoki E, et al. Effect of TRX-liposomes size on their prolonged circulation in rats. Chem Pharm Bull (Tokyo). 2003; 51: 336–338.

    Article  CAS  Google Scholar 

  25. Bredehorst R, Ligler FS, Kusterbeck AW, Chang EL, Gaber BP. Vogel CW. Effect of covalent attachment of immunoglobulin fragments on liposomal integrity. Biochemistry. 1986; 25: 5693–5698.

    Article  CAS  Google Scholar 

  26. Spragg DD, Alford DR, Greferath R, et al. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci USA. 1997; 94: 8795–8800.

    Article  CAS  Google Scholar 

  27. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA. 1987; 84: 6471–6475.

    Article  CAS  Google Scholar 

  28. Czyz M, Cierniewski CS. Selective Sp1 and Sp3 binding is crucial for activity of the integrin alpha v promoter in cultured endothelial cells. Eur J Biochem. 1999; 265: 638–644.

    Article  CAS  Google Scholar 

  29. Koning GA, Morselt HW, Velinova MJ, et al. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta. 1999; 1420: 153–167.

    Article  CAS  Google Scholar 

  30. Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer: 1996; 74: 1749–1756.

    CAS  Google Scholar 

  31. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 1997; 36: 66–75.

    Article  CAS  Google Scholar 

  32. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995; 55: 3752–3756.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Parenteral Medications Laboratories, Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center, TN, 26 S Dunlap St, Room 214, 38163, Memphis, TN

    Ramakrishna Nallamothu, George C. Wood & Laura A. Thoma

  2. Department of Mechanical Engineering, Temple University, Philadelphia, PA

    Christopher B. Pattillo, Robert C. Scott & Mohammad F. Kiani

  3. Department of Radiation Oncology, Temple University, Philadelphia, PA

    Mohammad F. Kiani

  4. Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center, Memphis, TN

    Bob M. Moore

Authors
  1. Ramakrishna Nallamothu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George C. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher B. Pattillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert C. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammad F. Kiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bob M. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Laura A. Thoma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramakrishna Nallamothu.

Additional information

Published: April 7, 2006

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nallamothu, R., Wood, G.C., Pattillo, C.B. et al. A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation. AAPS PharmSciTech 7, 32 (2006). https://doi.org/10.1208/pt070232

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1208/pt070232

Keywords

Search

Navigation